Drug
64Cu-DOTA-ECL1i
64Cu-DOTA-ECL1i is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(25%)
Terminated
1(25%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Terminated(1)
Other(1)
Detailed Status
Not yet recruiting1
unknown1
Terminated1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
not_yet_recruiting125%
unknown125%
terminated125%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_2
CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma
NCT07659678
recruiting
Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)
NCT07548099
terminatedphase_1
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
NCT04217057
unknownphase_1
Evaluation of CCR2 in Patients Post Myocardial Infarction
NCT05107596
Clinical Trials (4)
Showing 4 of 4 trials
NCT07659678Phase 2
CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma
NCT07548099
Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)
NCT04217057Phase 1
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
NCT05107596Phase 1
Evaluation of CCR2 in Patients Post Myocardial Infarction
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4